TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
GMAB

Genmab AS

Healthcare · Biotechnology

38.50$ +10.7% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Cash Flow

Genmab AS (GMAB) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at 51 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Cash Flow GMAB
Line item Q3 16 Q4 16 Q1 17 Q2 17 Q3 17 Q4 17 Q1 18 Q2 18 Q3 18 Q4 18 Q1 19 Q2 19 Q3 19 Q4 19 Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
205 -78 752 544 42 251 464 135 212 204 647 185 319 175 1,914 239 5,078 -798 1,185 355 447 241 587 959 1,968 398 3,235 436 2,037 1,672 219 219 2,033 326 287 62 536 300 3.0 51 890
– 41 – – – 48 – 102 14 88 7.0 7.0 7.0 146 7.0 8.0 10 241 11 15 14 264 15 16 22 163 21 131 85 58 13 14 112 13 16 16 18 21 29 26 94
14 14 17 20 21 18 21 22 22 26 36 32 35 44 45 53 51 51 61 81 86 82 90 118 118 113 115 156 162 153 24 27 186 20 25 33 34 36 49 37 156
– – – – – – – -89 12 -0.3 -165 126 -92 322 -186 1,247 481 -1,120 -422 639 194 -725 -227 -435 -361 945 552 552 23 – – – – – – – – – – – –
-11 -874 665 -35 -55 -311 103 -49 -47 -666 733 -33 -133 -2,225 1,824 -4,394 4,057 -1,181 500 -605 -651 -318 334 -513 -275 -1,669 2,857 -1,638 -559 80 61 -100 -524 16 75 -105 2.0 253 -113 -267 -125
1.5 25 3.9 36 27 22 29 19 409 21 21 15 46 20 58 145 46 58 28 79 77 68 57 68 82 110 104 97 98 67 4.0 4.0 48 27 30 10.0 2.0 13 5.0 3.0 23
-33 -480 -387 -332 25 27 -683 -104 -414 -576 -14 -772 -46 -1,151 9.0 919 -2,565 -714 -579 1,545 -1,621 -306 -667 -576 -1,382 -136 -13 -1,835 1,008 -442 -210 -1,270 224 114 -43 26 -54 -5,576 -9.0 2.0 -5,637
– – – – – – – 0.0 0.0 0.0 0.0 0.0 0.0 0.0 – – – – – – – – – – 78 157 32 71 36 – – – – – – – – – – – –
-118 0.1 – – – – -146 0.0 0.0 -11 -9.0 0.0 0.0 -14 -14 -4.0 -1.0 -6.0 -228 -249 -11 -9.0 -63 -211 -697 -11 -622 -35 -4.0 -6.0 -79 -438 -294 40 -83 -406 -24 0.4 -96 0.0 -120
– – – – – – – -8.3 -1.1 0.0 -7.2 -7.2 -7.2 -9.5 -8.0 -9.0 -13 -14 -12 -17 -21 -8.0 -16 -14 -17 -26 -29 -29 -16 – – – -2.0 0.6 -2.0 -4.0 -5.0 -2.0 -69 -65 -141
-16 26 103 90 14 6.7 -128 42 13 1.7 -11 27 3,636 8.0 15 4.0 19 33 -220 -240 24 16 -64 -214 -642 131 -611 7.0 20 -22 -85 -440 -276 41 -13 -406 -21 5,234 -178 -75 4,960
155 -490 457 267 55 261 -391 130 -191 -363 644 -594 4,060 -1,091 1,991 1,062 2,287 -1,632 632 1,585 -748 228 114 745 561 -484 2,395 -1,414 3,399 594 -77 -1,505 2,011 425 239 -323 465 -46 -194 -18 207
203 -103 748 508 15 229 435 116 -197 183 626 170 273 155 1,856 94 5,032 -856 1,157 276 370 173 530 891 1,886 288 3,131 339 1,939 1,605 215 215 1,985 299 257 52 534 287 -2.0 48 867

LTM = last twelve months (sum of the four most recent quarters).

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?